EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Schizophrenia Impacts and Treatment Priorities: Results of An Externally-Led Patient-Focused Drug Development Meeting Survey

Ilse S Peterson iD, Ramaa Chitale, Theresa Frangiosa, Holly B Krasa, Paulie VonEdWærd-Benjamin, Anita Fisher, Jessica T Markowitz, Arun Nagendra

Therapeutic Innovation & Regulatory Science · 2026-11 · 60 (6) · 1678-1686

DOI: 10.1007/s43441-026-01001-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 23.07.2026. Verfasst von Ilse S Peterson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faegre Drinker Consulting, 1500 K Street NW, Suite 1100, Washington, DC, 20005, USA. ilse.peterson@faegredrinker.com. Hauptthemen laut MEDLINE: Schizophrenia, Drug Development, Antipsychotic Agents. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Using survey data gathered for an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting led by the schizophrenia community to inform the US Food and Drug Administration, this publication examines schizophrenia’s impacts on daily life, reasons for discontinuation of medication, and desired outcomes of future medications.

Methods

An online, cross-sectional survey about schizophrenia’s impacts on daily life, treatment experiences, and desired outcomes of future medications was developed for adults with schizophrenia and caregivers of adults with schizophrenia who could not complete the survey. Patient advocacy organizations participating in the EL-PFDD meeting recruited respondents via email and social media between August 9, 2022 and September 26, 2022.

Results

282 survey responses from 96 people with schizophrenia and 186 caregiver proxies are reflected in this publication. Both respondent groups reported significant impacts of schizophrenia on aspects of daily living spanning work and education, relationships, responsibilities at home, and finances. For people with schizophrenia, the most frequently reported reason for discontinuing medications was weight gain (66% of 83 question respondents); for caregiver proxies, it was “feeling flat” (57% of 165 question respondents). Preventing delusions, preventing hallucinations, and enjoying daily activities received the highest average ratings as desired outcomes of future treatments from people with schizophrenia, whereas preventing delusions and making it easier to maintain relationships had the highest average ratings from caregiver proxies.

Conclusions

As exploratory work on community treatment priorities, this research can inform patient-focused drug development endeavors by patients, advocates, industry, and regulators to address unmet needs in schizophrenia moving forward.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaDrug DevelopmentAntipsychotic AgentsHumansCross-Sectional StudiesCaregiversAdultSurveys and QuestionnairesFemaleUnited StatesMaleMiddle AgedActivities of Daily Living

Stichwörter der Autor:innen

PFDDPatient-focused drug developmentSchizophreniaTreatment needs

Substanzen

Antipsychotic Agents

Autor:innen und Institutionen

  • Faegre Drinker Consulting, 1500 K Street NW, Suite 1100, Washington, DC, 20005, USA. ilse.peterson@faegredrinker.com.
  • Subcontractor to Faegre Drinker Consulting, Washington, DC, United States.
  • Faegre Drinker Consulting, 1500 K Street NW, Suite 1100, Washington, DC, 20005, USA.
  • Schizophrenia & Psychosis Action Alliance, Alexandria, VA, USA.
  • Blue Persimmon Group, Washington, DC, USA.
  • PFDD Meeting Co-Moderator & Diagnosee, Michigan, USA.

ORCID-Profile: Ilse S Peterson

Zitieren

APA

Peterson, I. S., Chitale, R., Frangiosa, T., Krasa, H. B., VonEdWærd-Benjamin, P., Fisher, A., Markowitz, J. T., & Nagendra, A. (2026). Schizophrenia Impacts and Treatment Priorities: Results of An Externally-Led Patient-Focused Drug Development Meeting Survey. Therapeutic Innovation & Regulatory Science, 60(6), 1678-1686. https://doi.org/10.1007/s43441-026-01001-2

Vancouver

Peterson IS, Chitale R, Frangiosa T, Krasa HB, VonEdWærd-Benjamin P, Fisher A, et al. Schizophrenia Impacts and Treatment Priorities: Results of An Externally-Led Patient-Focused Drug Development Meeting Survey. Therapeutic Innovation & Regulatory Science. 2026;60(6):1678-1686. doi:10.1007/s43441-026-01001-2

BibTeX
@article{Peterson2026,
  author = {Peterson, Ilse S and Chitale, Ramaa and Frangiosa, Theresa and Krasa, Holly B and VonEdWærd-Benjamin, Paulie and Fisher, Anita and Markowitz, Jessica T and Nagendra, Arun},
  title = {Schizophrenia Impacts and Treatment Priorities: Results of An Externally-Led Patient-Focused Drug Development Meeting Survey},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  volume = {60},
  number = {6},
  pages = {1678--1686},
  doi = {10.1007/s43441-026-01001-2}
}
Kostenlos starten →